Selecta Biosciences, a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced data from its ongoing Phase 2 trial of SEL-212 (SVP-Rapamycin in combination with the uricase enzyme pegsiticase), which … Continued
Today SQZ Biotech, a pre-clinical stage biotechnology company developing cell therapies, announced it was selected as a member of the 2017 class of World Economic Forum Technology Pioneers. SQZ is one of only thirty companies selected and was recognized for … Continued
Twist Bioscience Corporation, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced that it raised an additional $27 million in venture financing. This close, combined with the $33 million announced in March 2017, completes the $60 … Continued
Twist Bioscience has radically reduced the cost of working with DNA by retooling the technology used to synthesize it. This innovation could help lead to huge advances across a number of different applications. The research and testing carried out by … Continued
ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) in combination with FOLFOX chemotherapy for the treatment of patients with advanced pancreatic cancer. These data are being presented in … Continued
ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) in combination with immune checkpoint inhibitors for the treatment of patients with advanced non-small cell lung cancer (NSCLC) and metastatic … Continued
Emulate Inc. presented data today that shows expanded functionality in modeling viral infection on the Small Airway Lung-Chip. This advancement opens new opportunities for studying viral-induced exacerbations of asthma using a human-relevant system. The data demonstrates the capability to model … Continued
Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced Microsoft Corp. will purchase ten million strands of DNA from Twist Bioscience for expanded digital data storage research. The strands of DNA will be long-chain … Continued
Crocus Technology, a leading developer of TMR magnetic sensor technology and embedded MRAM, today announced that it has licensed advanced magnetic TMR technology to NXP Semiconductors, the global leader in automotive semiconductor solutions. TMR will help enable the next generation … Continued
Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced Dr. John Stuelpnagel, co-founder, first CEO and former COO of Illumina and a well-known genomics industry entrepreneur, will become Chairman of Muse bio’s Board of … Continued
Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that it has licensed LMB-100, a next-generation immunotoxin, from the Center for Cancer Research (CCR) at the NCI, part … Continued
Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced the appointment of Mark Daniels to the newly-created position of chief ethics and compliance officer. Mr. Daniels will maintain his current position as Twist Bioscience’s … Continued
ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced the appointment of Pierre Legault to its Board of Directors. Mr. Legault will serve as Chairman of the Audit Committee. “Pierre is an experienced executive and board member who has extensive knowledge … Continued
Emulate, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Food and Drug Administration’s (FDA) Office of Foods and Veterinary Medicine. Under this multi-year CRADA, Emulate and FDA will collaborate to … Continued
Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced that it raised an additional $33 million. To date, Twist Bioscience has raised a total of $166 million. “It is an exciting time to be … Continued
Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced the completion of a $23 million Series B financing. The oversubscribed financing was led by Venrock and included investments from Foresite Capital and Paladin Capital … Continued